¼¼°èÀÇ ¿¹¸£½Ã´Ï¾Æ Áø´Ü ½ÃÀå
Yersinia Diagnostics
»óǰÄÚµå : 1792898
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 480 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,242,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,727,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¿¹¸£½Ã´Ï¾Æ Áø´Ü ¼¼°è ½ÃÀåÀº 2030³â±îÁö 3¾ï 8,370¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 2¾ï 9,600¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¿¹¸£½Ã´Ï¾Æ Áø´Ü ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 3¾ï 8,370¸¸ ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 4.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¿¹¸£½Ã´Ï¾Æ Áø´Ü ±â±â´Â CAGR 3.7%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 2¾ï 5,780¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹¸£½Ã´Ï¾Æ Áø´Ü ŰƮ ¹× ½Ã¾à ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 6.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 8,060¸¸ ´Þ·¯, Áß±¹Àº CAGR 6.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¿¹¸£½Ã´Ï¾Æ Áø´Ü ½ÃÀåÀº 2024³â¿¡ 8,060¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 7,430¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.9%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.1%¿Í 4.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¿¹¸£½Ã´Ï¾Æ Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

½ÄÁßµ¶¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¿¹¸£½Ã´Ï¾Æ Áø´Ü ¼ö¿ä Áõ°¡?

°øÁß º¸°Ç ´ç±¹, ÀÓ»óÀÇ, ½Äǰ ¾ÈÀü ±ÔÁ¦ ´ç±¹ÀÌ ¿À¿°µÈ À½½Ä°ú ¹°¿¡¼­ ¹ß»ýÇÏ´Â ¼¼±Õ °¨¿°À» ¸·±â À§ÇÑ ³ë·ÂÀ» °­È­ÇÔ¿¡ µû¶ó ¼¼°è ¿¹¸£½Ã´Ï¾Æ Áø´Ü ½ÃÀåµµ ²ÙÁØÈ÷ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¿¹¸£½Ã´Ï¾Æ, ƯÈ÷ ¿¹¸£½Ã´Ï¾Æ ¿£Å×·ÎÄݸ®Æ¼Ä«¿Í ¿¹¸£½Ã´Ï¾Æ ½´µµÃ÷º£¸£±× Ŭ·Î½Ã½º´Â ƯÈ÷ ¼Ò¾Æ ¹× ¸é¿ª·ÂÀÌ ¾àÇÑ »ç¶÷¿¡°Ô¼­ À§Àå ÁúȯÀÇ ½É°¢ÇÑ ¿øÀÎÀ¸·Î Àνĵǰí ÀÖ½À´Ï´Ù. ÀÌ ¹ÚÅ׸®¾Æ´Â Á¾Á¾ °¡¿­ÀÌ ºÒÃæºÐÇÑ µÅÁö°í±â, Àú¿Â »ì±ÕµÇÁö ¾ÊÀº ¿ìÀ¯, 󸮵ÇÁö ¾ÊÀº ¹°°ú °ü·ÃÀÌ ÀÖÀ¸¸ç, °¨½Ã °³¼± ¹× Á¶±â ¹ß°ßÀÇ Áß¿äÇÑ ¸ñÇ¥°¡ µÇ°í ÀÖ½À´Ï´Ù. ½ÄÁßµ¶ÀÌ Àü ¼¼°èÀûÀ¸·Î ÀÇ·áºñ »ó½Â°ú »ý»ê¼º ÀúÇÏ¿¡ ±â¿©Çϰí ÀÖ´Â ¸¸Å­, ¿¹¸£½Ã´Ï¾Æ °¨¿°À» Á¶±â¿¡ Á¤È®ÇÏ°Ô Áø´ÜÇÏ´Â °ÍÀÌ °øÁߺ¸°ÇÀÇ ÃÖ¿ì¼± °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. Àμö°øÅëÀü¿°º´°ú Àü¿°º´ ¹ß»ý °¡´É¼º¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ º´¿ø, °Ë»ç±â°ü, ½Äǰ°Ë»ç±â°üÀÌ º¸´Ù °­·ÂÇÑ Áø´Ü µµ±¸¿¡ ÅõÀÚÇϵµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù. ±¹°¡ º¸°Ç ½Ã½ºÅÛÀÌ Áúº´ ÃßÀû ´É·ÂÀ» °­È­ÇÔ¿¡ µû¶ó ¼ÒÈ­±â °¨¿° Áø´Ü ÆÐ³Î¿¡ ¿¹¸£½Ã´Ï¾Æ¸¦ Æ÷ÇÔÇÏ´Â °ÍÀÌ ÀϹÝÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÏ»óÀûÀÎ Áø´ÜÀº ÀÓ»ó °Ë»ç½Ç»Ó¸¸ ¾Æ´Ï¶ó ±¹°æ°Ë»ç¼Ò, µ¿¹°º´¿ø, ½Äǰ°¡°ø½Ã¼³¿¡¼­µµ Áß¿äÇÏ°Ô ´Ù·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº ¿¹¸£½Ã´Ï¾Æ °ü·Ã Áúº´À» º¸´Ù È¿°úÀûÀ¸·Î ¿¹¹æÇÏ°í °ü¸®Çϱâ À§ÇÑ ³ë·ÂÀÇ Áõ°¡¸¦ ¹Ý¿µÇϸç, Áø´ÜÇÐÀº Çö´ë °¨¿°º´ ´ëÀÀ Àü·«ÀÇ ÃÖÀü¹æ ¹æ¾î ¼ö´ÜÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÐÀÚ °Ë»ç ¹× ¸é¿ªÃøÁ¤ °Ë»çÀÇ ±â¼ú ¹ßÀüÀº ¾î¶»°Ô °ËÃâ ´É·ÂÀ» Çâ»ó½Ã۰í Àִ°¡?

ÃÖ±Ù Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î ¿¹¸£½Ã´Ï¾Æ °ËÃâ¹ýÀÇ ¼Óµµ, ¹Î°¨µµ, ƯÀ̼ºÀÌ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. ÀüÅëÀûÀÎ ¹è¾ç ±â¹Ý ±â¼úÀº ÇöÀçµµ ³Î¸® »ç¿ëµÇ°í ÀÖÁö¸¸, º¸´Ù ºü¸£°í Á¤È®ÇÑ °á°ú¸¦ Á¦°øÇÏ´Â ºÐÀÚÁø´Ü ¹× ¸é¿ª ÃøÁ¤¹ýÀ¸·Î º¸¿ÏµÇ°í ÀÖ½À´Ï´Ù. ½Ç½Ã°£ PCR ¹× ¸ÖƼÇ÷º½º PCRÀ» Æ÷ÇÔÇÑ ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR) ±â¼úÀº ÀÓ»ó »ùÇÃÀ̳ª ȯ°æ »ùÇÿ¡¼­ Á÷Á¢, Á¾Á¾ ¸î ½Ã°£ ³»¿¡ ¿¹¸£½Ã´Ï¾Æ DNA¸¦ °ËÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â Àå½Ã°£ ¹è¾çÀÇ Çʿ伺À» ÁÙÀ̰í ÀÓ»óÀǰ¡ ´õ »¡¸® Ç¥Àû Ä¡·á¸¦ ½ÃÀÛÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø ºÐ¼®¹ý(ELISA)°ú Ãø¸é È帧 ºÐ¼®¹ýµµ ¿¤½Ã´Ï¾Æ±Õ¿¡ ƯÀÌÀûÀÎ Ç׿ø ¹× Ç×ü¸¦ È®ÀÎÇϱâ À§ÇØ °³¹ßµÇ¾úÀ¸¸ç, ÇöÀå Áø´Ü ¹× ´ë±Ô¸ð ½ºÅ©¸®´× ÇÁ·Î±×·¥ ¸ðµÎ¿¡ À¯¿ëÇÏ°Ô »ç¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¼¾¼­ ±â¼ú, ¹Ì¼¼À¯Ã¼ ÀåÄ¡, ·¦¿ÂĨ Ç÷§ÆûÀÇ Çõ½ÅÀº ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ¿¡¼­µµ µµÀÔÇÒ ¼ö ÀÖ´Â ÈÞ´ë°¡ °¡´ÉÇÏ°í »ç¿ëÀÚ Ä£È­ÀûÀÎ Áø´Ü µµ±¸¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÚµ¿È­ Ç÷§ÆûÀº Áß¾Ó ÁýÁᫎ ½ÇÇè½ÇÀÇ Ã³¸®·®À» ´õ¿í Çâ»ó½Ã۰í, ÀÎÀû ¿À·ù¸¦ ÁÙÀ̸ç, Ç¥ÁØÈ­¸¦ °³¼±ÇÕ´Ï´Ù. Áø´Ü ±â¾÷µéÀÌ ¿©·¯ º´¿ø±ÕÀ» µ¿½Ã¿¡ °ËÃâÇÒ ¼ö ÀÖ´Â ¸ÖƼÇ÷º½º ½Ã½ºÅÛ¿¡ ÁýÁßÇÔ¿¡ µû¶ó, ¿¤½Ã´Ï¾Æ±ÕÀº Á¾ÇÕÀûÀÎ ¼ÒÈ­°ü ÆÐ³Î¿¡ Æ÷ÇԵǴ °æ¿ì°¡ ¸¹¾ÆÁö°í ÀÖÀ¸¸ç, ±× °¡½Ã¼º°ú Áø´Ü ¼öÀ²ÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº °Ë»ç ¼±ÅÃÀÇ ÆøÀ» ³ÐÈú »Ó¸¸ ¾Æ´Ï¶ó, º¸´Ù ±¤¹üÀ§ÇÑ °¨½Ã¿Í ¹ßº´¿¡ ´ëÇÑ ½Å¼ÓÇÑ °øÁߺ¸°Ç ´ëÀÀÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½Äǰ ¾ÈÀü ±ÔÁ¦¿Í °¨½Ã °üÇàÀÇ º¯È­°¡ ½ÃÀå ¿ªÇп¡ ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

½Äǰ ¾ÈÀü ±ÔÁ¦¿Í °øÁß º¸°Ç °¨½ÃÀÇ ¼¼°èÀû º¯È­´Â Á¤È®ÇÏ°í ½Ã±âÀûÀýÇÑ ¿¹¸£½Ã´Ï¾Æ Áø´Ü ¾àǰ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ½ÄǰÀÇ ±¹Á¦ ¹«¿ªÀÌ È®´ëµÊ¿¡ µû¶ó ¼¼±Õ¼º º´¿øÃ¼°¡ ±¹°æÀ» ³Ñ¾î ÀüÆÄµÉ °¡´É¼ºÀÌ ³ô¾ÆÁö¸é¼­ °¢±¹Àº ´õ¿í ¾ö°ÝÇÑ ¼öÃâÀÔ °Ë»ç ¿ä°ÇÀ» ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. À¯·´½Äǰ¾ÈÀüû(EFSA), ¹Ì±¹ ½ÄǰÀǾ౹(FDA), ¼¼°èº¸°Ç±â±¸(WHO) µîÀÇ ±ÔÁ¦ ±â°üÀº ÀÏ»óÀûÀÎ ½Äǰ ¾ÈÀü °¨»çÀÇ ÀÏȯÀ¸·Î ¿¤½Ã´Ï¾Æ±Õ °ËÃâÀ» Æ÷ÇÔÇÑ °ß°íÇÑ ¹Ì»ý¹° ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ½Äǰ °¡°ø »ê¾÷Àº À§ÇØ¿ä¼Ò ºÐ¼® ¹× Áß¿ä°ü¸®Á¡(HACCP) ÇÁ·ÎÅäÄÝÀ» äÅÃÇϰí ÀÖÀ¸¸ç, ±ÔÁ¤ Áؼö¸¦ °ËÁõÇÏ°í ¼ÒºñÀÚ º¸È£¸¦ º¸ÀåÇϱâ À§ÇØ ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü ¹æ¹ýÀÌ ÇÊ¿äÇÕ´Ï´Ù. Àü±¹ÀûÀÎ Áúº´ °¨½Ã ½Ã½ºÅÛÀÌ °­È­µÇ¾î ¹ßº´À» ½Ç½Ã°£À¸·Î °¨ÁöÇÏ°í º¸°íÇÒ ¼ö ÀÖµµ·Ï °­È­µÇ°í ÀÖÀ¸¸ç, ¿¹¸£½Ã´Ï¾Æ´Â º¸°í Àǹ«°¡ ÀÖ´Â Áúº´À¸·Î µîÀçµÇ°í ÀÖ½À´Ï´Ù. ³óÀå¿¡¼­ ½ÄʱîÁö ÃßÀû °¡´É¼º¿¡ ´ëÇÑ ¿ä±¸´Â ³ó¾÷, µ¿¹° À§»ý, ½Äǰ »ý»ê ºÎ¹®¿¡ Áø´ÜÀÇ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼öÀÚ¿ø, Ãà»ê ȯ°æ, ½Äǰ »ý»ê ¶óÀÎÀÇ ¼¼±Õ ¿À¿° ¹°Áú ÆÄ¾ÇÀ» À§ÇÑ È¯°æ ¸ð´ÏÅ͸µÀ¸·Î ¿¹¸£½Ã´Ï¾Æ Áø´ÜÀÇ Àû¿ë ¹üÀ§´Â º´¿ø ¿Ü¿¡µµ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦Àû ¾Ð·Â°ú ¸ð´ÏÅ͸µ ÀÌ´Ï¼ÅÆ¼ºê´Â Áø´Ü µµ±¸¿Í ÀÎÇÁ¶ó¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ¸¦ À§ÇÑ °­·ÂÇÑ ±â¹ÝÀ» ±¸ÃàÇÏ¿© ¼¼±Õ °¨¿°¿¡ ´ëÇÑ °øÁߺ¸°Ç ´ëÀÀÀÌ ¿¹¹æÀûÀ̰í È¿°úÀûÀ¸·Î À¯ÁöµÉ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù.

¿¹¸£½Ã´Ï¾Æ Áø´Ü ½ÃÀåÀÇ Àå±âÀû ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ÇÙ½É µ¿ÀÎÀº ¹«¾ùÀΰ¡?

¿¹¸£½Ã´Ï¾Æ Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ÇコÄɾî ÀνÄ, ±â¼ú Çõ½Å, °ø°ø¾ÈÀü ¿ì¼±¼øÀ§, ¼¼°è º¸°Ç ÀÌ´Ï¼ÅÆ¼ºê¿Í °ü·ÃµÈ ¿©·¯ °¡Áö ¼ö·Å ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎÀº ƯÈ÷ Àα¸ ¹ÐÁý Áö¿ª°ú ÀÚ¿øÀÌ ºÎÁ·ÇÑ Áö¿ª¿¡¼­ ¿À¿°µÈ À½½Ä°ú ¹°°ú °ü·ÃµÈ À§À庴 ¹ß»ý·üÀÇ Áõ°¡ÀÔ´Ï´Ù. ½ÄÁßµ¶¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Á¶±â °Ç°­°ü¸®¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁ³°í, ÀÌ¿¡ µû¶ó Á¢±Ù¼ºÀÌ ³ô°í Á¤È®ÇÑ Áø´Ü¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÇ·áÁøÀÌ Áõ»óÀÇ ±Ùº» ¿øÀÎÀ» ½Å¼ÓÇÏ°Ô ÆÄ¾ÇÇÏ°í ºÒÇÊ¿äÇÑ Ç×»ýÁ¦ »ç¿ëÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ ÀÓ»ó ÇöÀå¿¡¼­ º¸´Ù Á¾ÇÕÀûÀÎ Áø´Ü ÆÐ³ÎÀÌ ¿ä±¸µÇ°í ÀÖ´Â °Íµµ Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù. ÀΰøÁö´É°ú µ¥ÀÌÅÍ ºÐ¼®ÀÇ ÅëÇÕÀ» Æ÷ÇÔÇÑ Áø´Ü Ç÷§ÆûÀÇ ¹ßÀüÀº º¸´Ù ºü¸¥ ÇØ¼®°ú Áø´Ü Á¤È®µµ Çâ»óÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¿¬±¸±â°ü, °øÁߺ¸°Ç±â°ü, »ý¸í°øÇÐ ±â¾÷ °£ÀÇ Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ÅëÇØ »õ·Î¿î ºÐ¼®¹ý °³¹ßÀ» °¡¼ÓÈ­ÇÏ°í ½ÃÀå °³Ã´À» È®´ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àü ¼¼°è°¡ Àü¿°º´ ´ëºñ ¹× Ç×±ÕÁ¦ ³»¼º(AMR) °¨½Ã¸¦ °­È­ÇÏ·Á´Â ³ë·ÂÀ¸·Î ÀÎÇØ ±¤¹üÀ§ÇÑ °¨¿° ¸ð´ÏÅ͸µ Àü·«ÀÇ ÀÏȯÀ¸·Î ¿¹¸£½Ã´Ï¾Æ¸¦ Æ÷ÇÔÇÑ º´¿øÃ¼ ŽÁö ½Ã½ºÅÛ¿¡ ´ëÇÑ ÅõÀÚ°¡ Àå·ÁµÇ°í ÀÖ½À´Ï´Ù. ±³À° Ä·ÆäÀΰú ÈÆ·Ã ÇÁ·Î±×·¥À» ÅëÇØ °Ë»ç ±â¼úÀÚ¿Í ÀÇ·áÁøÀÌ ¿¹¸£½Ã´Ï¾Æ °¨¿°À» È¿°úÀûÀ¸·Î ÀνÄÇÏ°í °Ë»çÇÒ ¼ö ÀÖ´Â ´É·ÂÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕµÇ¾î ½ÃÀå ȯ°æÀº °ß°íÇϰí È®Àå °¡´ÉÇϸç, ±â¼ú Çõ½Å, Á¤Ã¥°úÀÇ Àϰü¼º, °øÁß º¸°ÇÀÇ ¿ì¼± ¼øÀ§°¡ °áÇյǾî Áö¼ÓÀûÀÎ ¼ºÀå°ú °ü·Ã¼ºÀ» °¡Á®¿Ô½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(¿¹¸£½Ã´Ï¾Æ Áø´Ü ±â±â, ¿¹¸£½Ã´Ï¾Æ Áø´Ü ŰƮ ¹× ½Ã¾à), Áø´Ü °Ë»ç(º¯ ¹è¾ç °Ë»ç, ¿µ»ó °Ë»ç, Ç÷ûÇÐÀû °Ë»ç, ´ëÀå³»½Ã°æ °Ë»ç, ±âŸ Áø´Ü °Ë»ç), ±â¼ú(¸é¿ªÃøÁ¤¹ý ±â¼ú, DNA ÇÁ·Îºê ±â¼ú, ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ ±â¼ú, À¯¼¼Æ÷ ºÐ¼® ±â¼ú, Å©·Î¸¶Åä±×·¡ÇÇ ±â¼ú, ±âŸ ±â¼ú), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, °øÁßÀ§»ý ¿¬±¸¼Ò ÃÖÁ¾»ç¿ëÀÚ, »ó¾÷ ¿¬±¸¼Ò ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Yersinia Diagnostics Market to Reach US$383.7 Million by 2030

The global market for Yersinia Diagnostics estimated at US$296.0 Million in the year 2024, is expected to reach US$383.7 Million by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Yersinia Diagnostic Instruments, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$257.8 Million by the end of the analysis period. Growth in the Yersinia Diagnostic Kits & Reagents segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$80.6 Million While China is Forecast to Grow at 6.9% CAGR

The Yersinia Diagnostics market in the U.S. is estimated at US$80.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$74.3 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.1% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Yersinia Diagnostics Market - Key Trends & Drivers Summarized

Is Growing Awareness of Foodborne Diseases Fueling the Demand for Yersinia Diagnostics?

The global Yersinia diagnostics market is expanding steadily as public health authorities, clinicians, and food safety regulators intensify their efforts to combat bacterial infections that arise from contaminated food and water. Yersinia, particularly Yersinia enterocolitica and Yersinia pseudotuberculosis, is increasingly recognized as a significant cause of gastrointestinal illness, particularly in children and immunocompromised individuals. The bacterium is often associated with undercooked pork, unpasteurized milk, and untreated water, making it a key target for improved surveillance and early detection. With foodborne diseases contributing to rising healthcare costs and productivity losses globally, early and accurate diagnosis of Yersinia infections is becoming a public health priority. Increased awareness about zoonotic transmission and potential outbreaks is also prompting hospitals, laboratories, and food testing agencies to invest in more robust diagnostic tools. As national health systems strengthen their disease tracking capabilities, the inclusion of Yersinia in diagnostic panels for gastrointestinal infections is becoming more commonplace. Routine diagnostics are being emphasized not only in clinical laboratories but also in border inspection posts, veterinary centers, and food processing facilities. These efforts reflect a growing commitment to preventing and managing Yersinia-related illnesses more effectively, positioning diagnostics as a frontline defense in modern infectious disease control strategies.

How Are Technological Advances in Molecular and Immunoassay Testing Enhancing Detection Capabilities?

Recent advances in diagnostic technology are significantly improving the speed, sensitivity, and specificity of Yersinia detection methods. Traditional culture-based techniques, while still widely used, are increasingly being supplemented by molecular diagnostics and immunoassays that offer quicker and more precise results. Polymerase chain reaction (PCR) techniques, including real-time and multiplex PCR, allow for the detection of Yersinia DNA directly from clinical or environmental samples, often within a matter of hours. These tests reduce the need for extended incubation periods and help clinicians initiate targeted treatments much sooner. Enzyme-linked immunosorbent assays (ELISAs) and lateral flow assays are also being developed to identify Yersinia-specific antigens or antibodies, making them valuable for both point-of-care diagnostics and large-scale screening programs. Innovations in biosensor technology, microfluidic devices, and lab-on-a-chip platforms are contributing to portable and user-friendly diagnostic tools that can be deployed in resource-limited settings. Automated platforms are further enhancing throughput in centralized laboratories, reducing human error and improving standardization. As diagnostic companies focus on multiplex systems that can simultaneously detect multiple pathogens, Yersinia is increasingly included in comprehensive gastrointestinal panels, increasing its visibility and diagnostic yield. These technological innovations are not only expanding the range of testing options available but are also facilitating broader surveillance and quicker public health responses to outbreaks.

Are Shifts in Food Safety Regulations and Surveillance Practices Impacting Market Dynamics?

Global shifts in food safety regulations and public health surveillance are playing a critical role in driving demand for accurate and timely Yersinia diagnostics. As international trade in food products expands, so does the potential for cross-border transmission of bacterial pathogens, prompting countries to implement stricter import and export testing requirements. Regulatory agencies such as the European Food Safety Authority (EFSA), the U.S. Food and Drug Administration (FDA), and the World Health Organization (WHO) are emphasizing the importance of robust microbiological monitoring systems that include Yersinia detection as part of routine food safety audits. Food processing industries are adopting hazard analysis and critical control point (HACCP) protocols that require reliable diagnostic methods to verify compliance and ensure consumer protection. National disease surveillance systems are being strengthened to detect and report outbreaks in real time, with Yersinia increasingly listed as a reportable disease. The demand for traceability from farm to fork is creating opportunities for diagnostics in agriculture, animal health, and food production sectors. Additionally, environmental monitoring initiatives aimed at identifying bacterial contaminants in water sources, livestock environments, and food production lines are expanding the application of Yersinia diagnostics beyond hospitals. These regulatory pressures and monitoring initiatives are creating a strong foundation for sustained investment in diagnostic tools and infrastructure, ensuring that public health responses to bacterial infections remain proactive and effective.

What Core Drivers Are Supporting Long-Term Growth in the Yersinia Diagnostics Market?

The growth in the Yersinia diagnostics market is driven by multiple converging factors related to healthcare awareness, technological innovation, public safety priorities, and global health initiatives. A primary driver is the increasing incidence of gastrointestinal infections linked to contaminated food and water, particularly in densely populated and low-resource regions. Rising consumer awareness around foodborne illnesses is prompting earlier healthcare engagement, which in turn boosts demand for accessible and accurate diagnostics. Another important factor is the push for more comprehensive diagnostic panels in clinical settings, as healthcare providers seek to identify the root cause of symptoms quickly and minimize unnecessary use of antibiotics. Advances in diagnostic platforms, including the integration of artificial intelligence and data analytics, are also enabling faster interpretation and improved diagnostic accuracy. Strategic partnerships between research institutions, public health agencies, and biotechnology firms are accelerating the development of novel assays and expanding market access. Furthermore, global efforts to strengthen pandemic preparedness and antimicrobial resistance (AMR) surveillance are encouraging investments in pathogen detection systems that include Yersinia as part of a broader infectious disease monitoring strategy. Educational campaigns and training programs are increasing the capacity of laboratory technicians and healthcare workers to recognize and test for Yersinia infections effectively. Together, these factors are establishing a robust and scalable market landscape for Yersinia diagnostics, where innovation, policy alignment, and public health priorities collectively drive continued growth and relevance.

SCOPE OF STUDY:

The report analyzes the Yersinia Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Yersinia Diagnostic Instruments, Yersinia Diagnostic Kits & Reagents); Diagnostic Test (Stool Culture Test, Imaging Tests, Serological Tests, Colonoscopy Test, Other Diagnostic Tests); Technology (Immunoassay Technology, DNA Probes Technology, Polymerase Chain Reaction Technology, Flow Cytometry Technology, Chromatography Technology, Other Technologies); End-Use (Hospitals End-Use, Public Health Laboratories End-Use, Commercial Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â